Status:
COMPLETED
Efficacy of Formulated Posterior Sub Tenon Triamcinolone in Macular Edema Secondary to Non-Ischemic Retinal Vein Occlusions
Lead Sponsor:
Al-Azhar University
Conditions:
Retinal Vein Occlusion
Eligibility:
All Genders
50-69 years
Phase:
NA
Brief Summary
Retinal vein occlusion (RVO) is considered the second vascular disorder of the retina after diabetic retinopathy. Patients with RVO are at risk of the development of macular edema. Different treatment...
Eligibility Criteria
Inclusion
- Diminution of vision due to macular edema secondary to non-ischemic retinal vein occlusions, either central or branch
- CMT ≥ 250 µ,
- Willing to participate in the study.
Exclusion
- Unwilling to participate in the study
- Ischemic RVO
- previous laser treatment
- Glaucoma, macular ischemia, cataract, vitreous hemorrhage, and neovascularization of the iris
- patients with previous anti VEGFs or steroid injections or any eye surgery three months before the inclusion
- Cardiac co-morbidities result in significant hemodynamic changes
- Respiratory diseases need treatment with antibiotics
- Suffering from other chronic diseases as diabetes
- Patient with allergy from triamcinolone acetonide.
Key Trial Info
Start Date :
March 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 30 2022
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT05345808
Start Date
March 1 2021
End Date
March 30 2022
Last Update
April 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Akram Fekry Elgazzar
Damietta, Egypt, 34517